Search clinical trials for: CC-99282

Total 835 results

Celgene

Active, not recruiting

A Study to Determine Dose, Safety, Tolerability, Drug Levels, and Efficacy of CC-220 Monotherapy, and in Combination With Other Treatments in Participants With Multiple Myeloma

Multiple Myeloma

United States, Australia, Canada, France, Germany, Israel, Italy, Japan, Netherlands, Spain, United Kingdom
Andrei Iagaru
National Cancer Institute (NCI); National Institutes of Health (NIH)

Terminated

HDR Brachytherapy 68-Ga-RM2 PET, 68-Ga-PSMA-11 PET &Multi Parametric MRI in Prostate Cancer

Prostate Cancer

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Active, not recruiting

Obinutuzumab and Lenalidomide in Treating Patients With Previously Untreated Stage II-IV Grade 1-3a Follicular Lymphoma

Fatigue | Weight Loss | Fever | Splenomegaly | Ann Arbor Stage II Grade 1 Follicular Lymphoma | Ann Arbor Stage II Grade 2 Follicular Lymphoma | Grade 3a Follicular Lymphoma | Ann Arbor Stage III Grade 1 Follicular Lymphoma | Ann Arbor Stage III Grade 2 Follicular Lymphoma | Ann Arbor Stage IV Grade 1... and other conditions

United States
George Washington University
Celgene Corporation

Withdrawn

Apremilast and Moderate to Severe Chronic Hand Dermatitis (CHD)

Chronic Hand Dermatitis

United States
Amgen

Completed

Effects of Age and Sex on the Pharmacokinetics of Apremilast in Healthy Adults

Healthy Volunteer

United States
Amgen

Completed

Phase II Study of Apremilast (CC-10004) in Adults With in Psoriatic Arthritis

Psoriatic Arthritis

Belgium, Canada, United Kingdom, Germany, Netherlands
University of Wisconsin, Madison
Celgene Corporation

Completed

Study of Bendamustine/Rituxan Induction Chemotherapy With Revlimid Maintenance for Relapsed/Refractory CLL and SLL

Chronic Lymphocytic Leukemia | Small Lymphocytic Lymphoma

United States
M.D. Anderson Cancer Center
Celgene

Completed

Lenalidomide in Combination With Bevacizumab, Sorafenib, Temsirolimus, or 5-Fluorouracil, Leucovorin, Oxaliplatin (FOLFOX)

Advanced Cancers

United States
Amgen

Recruiting

A Study of Apremilast in Pediatric Participants in Children With Mild to Moderate Plaque Psoriasis

Plaque Psoriasis

United States
Amgen

Recruiting

A Study of Apremilast in Children With Oral Ulcers Associated With Behçet's Disease or Juvenile Psoriatic Arthritis

Juvenile Psoriatic Arthritis | Behçet's Disease

Spain, Turkey, Israel, Greece
Amgen

Completed

A Phase 3B, Open-label, Single-arm Study of the Efficacy and Safety of Apremilast, in Subjects With Plaque Psoriasis That is Not Adequately Controlled by Topical Therapy

Plaque Psoriasis

Japan, Germany
Amgen

Completed

A Phase 3 Randomized, Double-blind Study to Evaluate the Efficacy and Safety of Apremilast (CC-10004) in Subjects With Active Behçet's Disease

Behçet's Syndrome

United States, Korea, Republic of, Israel, Italy, Turkey, France, Germany, Greece, Lebanon, Japan
Amgen

Completed

Study to Evaluate the Pharmacokinetics of Single and Multiple Doses of Apremilast in Healthy Adult Male Korean Subjects

Pharmacokinetics

Korea, Republic of
Amgen

Completed

Effect of Food on the Pharmacokinetics of Apremilast (CC-10004) in Healthy Adults

Healthy Volunteer

United States
Celgene Corporation
Prologue Research International

Terminated

Phase I/II Open-Label, Dose Escalation Study To Determine The Maximum Tolerated Dose And To Evaluate The Safety Profile of Lenalidomide (Revlimid® CC-5013) With Liposomal Doxorubicin In Subjects With Advanced Ovarian and Primary Peritoneal Carcinoma

Ovarian Cancer

United States
Amgen

Terminated

Efficacy and Safety Study of Apremilast (CC-10004) in Pediatric Subjects From 6 Through 17 Years of Age With Moderate to Severe Plaque Psoriasis

Psoriasis

United States, Belgium, Spain, Czechia, Canada, Italy, Israel, France, Netherlands, Russian Federation
Mayo Clinic
National Cancer Institute (NCI)

Completed

Nivolumab and Pomalidomide in Treating Patients With Relapsed or Refractory Central Nervous System Diffuse Large B Cell Lymphoma or Primary Vitreoretinal Diffuse Large B Cell Lymphoma

Recurrent Nervous System Lymphoma | Recurrent Primary Vitreoretinal DLBCL | Refractory Nervous System Lymphoma | Refractory Primary Vitreoretinal DLBCL

United States
M.B.A. van Doorn
Celgene

Completed

Short-term Safety, Efficacy and Mode of Action of Apremilast in Moderate Suppurative Hidradenitis (SMASH)

Hidradenitis Suppurativa

Netherlands
Celgene Corporation

Completed

Japanese Phase 2 Study to Evaluate the Efficacy and Safety of Pomalidomide in Subjects With Relapsed and Refractory Multiple Myeloma

Multiple Myeloma

Japan
Ohio State University Comprehensive Cancer Center
Novartis; Celgene

Completed

A Phase II Trial of Panobinostat and Lenalidomide in Patients With Relapsed or Refractory Hodgkin's Lymphoma

Recurrent Adult Hodgkin Lymphoma | Adult Lymphocyte Depletion Hodgkin Lymphoma | Adult Lymphocyte Predominant Hodgkin Lymphoma | Adult Mixed Cellularity Hodgkin Lymphoma | Adult Nodular Sclerosis Hodgkin Lymphoma | Adult Nodular Lymphocyte Predominant Hodgkin Lymphoma

United States
National Cancer Institute (NCI)

Completed

Lenalidomide and Prednisone in Treating Patients With Myelofibrosis

Primary Myelofibrosis | Polycythemia Vera | Essential Thrombocythemia

United States
Celgene

Active, not recruiting

A Study to Determine the Recommended Dose and Regimen and to Evaluate the Safety and Preliminary Efficacy of CC-92480 in Combination With Standard Treatments in Participants With Relapsed or Refractory Multiple Myeloma (RRMM) and Newly Diagnosed Multiple Myeloma (NDMM)

Multiple Myeloma

United States, Canada, Italy, Czechia, Denmark, France, Germany, Greece, Spain
Massachusetts General Hospital
Celgene; OncoPep, Inc.

Active, not recruiting

A Study of PVX-410, a Cancer Vaccine, and Citarinostat +/- Lenalidomide for Smoldering MM

Smoldering Multiple Myeloma

United States
Amgen

Completed

Safety and Efficacy Study of Apremilast to Treat Psoriatic Arthritis

Psoriatic Arthritis

Spain, Canada, United States, Czechia, Russian Federation, Hungary, Australia, New Zealand, Estonia, Romania
Amgen

No longer available

Expanded Access for CC-10004

Bechet's Disease

United States
Centre Hospitalier Régional d'Orléans

Terminated

Cervical Arthroplasty "Fixed Core" Versus "Movable Core": Clinical and Radiological Impact in the Medium Term (DISC-C)

Back Pain | Neck Pain

France
ShangHai Ji Ai Genetics & IVF Institute

Unknown

Effects of Clomiphene Citrate Ovulation Induction on Frozen Embryo Transfer

Infertility, Female | Clomiphene Citrate

China
European Myeloma Network

Completed

Sequential Trial on Reduced Intensity Conditioning (RIC) Allogeneic Transplantation (EMN-alloRIC)

Multiple Myeloma | Hematologic Malignancies

Spain, Sweden, Germany, Italy
Istituto Nazionale Tumori IRCCS - Fondazione G....

Unknown

A Phase 1/2 Study of Lenalidomide in Combination With Bendamustine in Relapsed and Primary Refractory Hodgkin Lymphoma (LEBEN)

Recurrent Adult Hodgkin Lymphoma

Italy
Weill Medical College of Cornell University
Merck Sharp & Dohme LLC; United States Department of Defense

Recruiting

Phase I/II Trial of Pembrolizumab and Androgen-receptor Pathway Inhibitor With or Without 225Ac-J591 for Progressive Metastatic Castration Resistant Prostate Cancer

Prostate Cancer

United States
Celgene

Completed

A Safety Confirmation Study on Lenalidomide With Dexamethasone In Japanese Patients With Previously Treated Multiple Myeloma

Multiple Myeloma

Japan
Massachusetts General Hospital
Dana-Farber Cancer Institute

Completed

Lenalidomide Plus Bendamustine and Rituximab for Untreated CLL/SLL

Chronic Lymphocytic Leukemia | Small Lymphocytic Lymphoma | B Chronic Lymphocytic Leukemia

United States
City of Hope Medical Center

Terminated

Vorinostat and Lenalidomide in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma or Non-Hodgkin Lymphoma

Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue | Nodal Marginal Zone B-cell Lymphoma | Recurrent Adult Burkitt Lymphoma | Recurrent Adult Diffuse Large Cell Lymphoma | Recurrent Adult Diffuse Mixed Cell Lymphoma | Recurrent Adult Diffuse Small Cleaved Cell Lymphoma and other conditions

United States
David Bond, MD
Bristol-Myers Squibb

Active, not recruiting

Nivolumab and Lenalidomide in Treating Patients With Relapsed or Refractory Non-Hodgkin or Hodgkin Lymphoma

Recurrent Grade 1 Follicular Lymphoma | Recurrent Grade 2 Follicular Lymphoma | Recurrent Mantle Cell Lymphoma | Recurrent Marginal Zone Lymphoma | Recurrent Diffuse Large B-Cell Lymphoma | Refractory Diffuse Large B-Cell Lymphoma | Refractory Mantle Cell Lymphoma | Recurrent Burkitt Lymphoma | Recurrent... and other conditions

United States
Celgene

Terminated

A Phase I/II Study to Determine the Maximum Tolerated Dose (MTD) and Safety of CC-4047 (Pomalidomide) Administered in Conjunction With Cisplatin and Etoposide

Carcinoma, Small Cell

United States, Canada
Celgene

Completed

CC-223 and Ketoconazole Drug-Drug Interaction Study

Healthy Volunteers
M.D. Anderson Cancer Center
Celgene

Completed

Pomalidomide for Myelofibrosis Patients

Polycythemia Vera | Thrombocythemia

United States
Celgene

Completed

A Phase 3, Multicenter, Randomized, Open-Label Study to Compare the Efficacy and Safety of Pomalidomide in Combination With Low-Dose Dexamethasone Versus High-Dose Dexamethasone in Subjects With Refractory Multiple Myeloma or Relapsed and Refractory Multiple Myeloma and Companion Study (NIMBUS)

Multiple Myeloma

United States, Netherlands, Canada, Belgium, United Kingdom, Australia, Denmark, Germany, Spain, Switzerland, France, Italy, Greece, Russian Federation, Sweden, Czechia
Mayo Clinic
National Cancer Institute (NCI)

Completed

CC-4047 and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma or Amyloidosis

Multiple Myeloma and Plasma Cell Neoplasm

United States
Celgene

Completed

CC-5013 Plus Dexamethasone Versus Dexamethasone Alone in Previously Treated Subjects With Multiple Myeloma

Multiple Myeloma

United States, Canada
National Cancer Institute (NCI)

Active, not recruiting

Lenalidomide With or Without Epoetin Alfa in Treating Patients With Myelodysplastic Syndrome and Anemia

Anemia | Chronic Myelomonocytic Leukemia | Myelodysplastic Syndrome | de Novo Myelodysplastic Syndrome

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Completed

Lenalidomide and Obinutuzumab in Treating Patients With Relapsed Indolent Non-Hodgkin Lymphoma

Recurrent Grade 1 Follicular Lymphoma | Recurrent Grade 2 Follicular Lymphoma | Recurrent Grade 3 Follicular Lymphoma | Recurrent Marginal Zone Lymphoma | Recurrent Small Lymphocytic Lymphoma | Refractory Small Lymphocytic Lymphoma | Recurrent Follicular Lymphoma | Refractory Follicular Lymphoma | Refractory... and other conditions

United States
Criterium, Inc.
Celgene Corporation; Amgen

Terminated

A Safety and Efficacy Study of Carfilzomib and Pomalidomide With Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma

Multiple Myeloma

United States
Roswell Park Cancer Institute
Celgene Corporation

Completed

Lenalidomide and Cytarabine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia

Recurrent Adult Acute Myeloid Leukemia | Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities | Adult Acute Myeloid Leukemia With Del(5q) | Adult Acute Myeloid Leukemia With Inv(16)(p13;q22) | Adult Acute Myeloid Leukemia With t(16;16)(p13;q22) | Adult Acute Myeloid Leukemia With t(8... and other conditions

United States
Shiraz University of Medical Sciences

Completed

Effects of Cyproterone Compound-spironolactone, Metformin and Pioglitazone on Inflammatory Markers in PCOS (AntiPCO)

Polycystic Ovary Syndrome

Iran, Islamic Republic of
Fred Hutchinson Cancer Center
National Cancer Institute (NCI)

Terminated

Lenalidomide With or Without Rituximab in Treating Patients With Progressive or Relapsed Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Prolymphocytic Leukemia, or Non-Hodgkin Lymphoma Previously Treated With Donor Stem Cell Transplant

Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue | Nodal Marginal Zone B-cell Lymphoma | Recurrent Adult Burkitt Lymphoma | Recurrent Adult Diffuse Large Cell Lymphoma | Recurrent Adult Diffuse Mixed Cell Lymphoma | Recurrent Adult Diffuse Small Cleaved Cell Lymphoma and other conditions

United States
RenJi Hospital
The First Affiliated Hospital with Nanjing Medical University; The First Affiliated... and other collaborators

Recruiting

PVd Versus Vd in NDMM Patients With RI

Multiple Myeloma

China
Northwestern University
National Cancer Institute (NCI); Celgene

Active, not recruiting

Romidepsin and Lenalidomide in Treating Patients With Previously Untreated Peripheral T-Cell Lymphoma

Peripheral T-cell Lymphoma | Anaplastic Large Cell Lymphoma | Angioimmunoblastic T-cell Lymphoma | Adult Nasal Type Extranodal NK/T-cell Lymphoma | Hepatosplenic T-cell Lymphoma | Stage III Cutaneous T-cell Non-Hodgkin Lymphoma | Stage IV Cutaneous T-cell Non-Hodgkin Lymphoma | Stage I Cutaneous... and other conditions

United States
Yvonne Efebera
Bristol-Myers Squibb; National Cancer Institute (NCI); American Cancer Society...

Terminated

Lenalidomide and Nivolumab in Treating Patients With Relapsed or Refractory Multiple Myeloma

Refractory Plasma Cell Myeloma | Recurrent Plasma Cell Myeloma

United States
Bristol-Myers Squibb

Recruiting

A Study to Evaluate Safety, Drug Levels and Effectiveness of CC-92480 (BMS-986348) in Combination With Other Treatments in Participants With Relapsed or Refractory Multiple Myeloma

Multiple Myeloma

Norway, United States, Spain, United Kingdom, Canada

Search clinical trials for: CC-99282

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Pakistan

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations